Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 study by Arthur Bobin, Salomon Manier, Joe de Keizer, Jaydeep K. Srimani, Cyrille Hulin, Lionel Karlin, Denis Caillot, Ingrid Lafon, Clara Mariette, Carla Araujo, Bertrand Arnulf, Benoît Bareau, Karim Belhadj, Lofti Benboubker, Thorsten Braun, Claire Calmettes, Olivier Decaux, Mamoun Dib, Hélène Demarquette, Caroline Jacquet, Cécile Sonntag, Sophie Godet, Arnaud Jaccard, Pascal Lenain, Margaret Macro, Valentine Richez-Olivier, Mourad Tiab, Laure Vincent, Hacene Zerazhi, Marie-Odile Pétillon, Sandrine Rollet, Helene Gardeney, Geraldine Durand, Anthony Levy, Cyrille Touzeau, Aurore Perrot, Philippe Moreau, Thierry Facon, Jill Corre, Stephanie Ragot, Herve Avet-Loiseau, Xavier Leleu

Get full text